Last reviewed · How we verify
NCT04433936
Corneal Tomographic Parameters in TGD
trial testing Pentacam tomography in Keratoconus in 100 participants. Completed in 1 June 2018.
1 June 2018
Quick facts
| Lead sponsor | Ameera Gamal Abdelhameed |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 February 2018 |
| Primary completion | 1 June 2018 |
| Estimated completion | 1 June 2018 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Pentacam tomography
Conditions studied
- Keratoconus — all drugs for Keratoconus →
- Corneal Ectasia — all drugs for Corneal Ectasia →
- Thyroid Eye Disease — all drugs for Thyroid Eye Disease →
Sponsor
Ameera Gamal Abdelhameed — full company profile →
Who can join
Eligibility, any sex, with Keratoconus or Corneal Ectasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The current study involved analysis of the corneal tomographic parameters of patients with thyroid gland dysfunction (hyperthyroidism or hypothyroidism), including those with an autoimmune etiology, in comparison to healthy controls without TGD, using pentacam, in an attempt to detect possible early corneal changes and to highlight whether early screening of those patients would be necessary for early detection of KC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04433936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Keratoconus
Currently open trials in the same condition.
- NCT07372911 — PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus · NA · recruiting
- NCT07461129 — Electrophysiological Changes in Cases of Different Stages of Keratoconus · active not recruiting
- NCT06601101 — Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus · Phase 3 · recruiting
- NCT05516004 — Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning · Phase 2 · recruiting
- NCT06798779 — Predicting Manifest Astigmatism in Keratoconus Patients. · active not recruiting
Other Ameera Gamal Abdelhameed trials
Trials by the same sponsor.
- NCT04539106 — Intravitreal Ranibizumab in Recurrent ROP · completed
- NCT04537065 — Long Term Outcome of Intravitreal Ranibizumab for ROP · completed
- NCT04430647 — Phaco-UCP Versus Phaco Alone for OAG and Cataract · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04433936 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ameera Gamal Abdelhameed
- Last refreshed: 16 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04433936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing